Abstract Submission Form


Presenter Information’s

Biography (Brief Presenter biography highlighting in 75 word limit career and presentation experience)
Ex. 2014-current: Associate professor in University of Buea, 2010-2014: Senior lecturer in University of Buea, 2008-2010: Lecturer in University of Buea

Title of Abstract, Authors and theirs Affiliation (required)

Ex.
Identification and characterization of in vivo released products of Onchocerca with diagnostic potential, and use of monoclonal antibodies

Fidelis Cho-Ngwa1,*, Xhu Xiang2, Jonathan A. Metuge1, Annika Daggfeldt3, Kjell-Olov Grönvik3, Vincent P. Titanji1

1, Biotechnology Unit, Faculty of Science, University of Buea, P.O. Box 63 Buea, Cameroon;

2, CCRC, U of Georgia (GA), USA;

3, Department of Virology, Immunobiology and Parasitology, National Veterinary Institute (SVA), Uppsala, Sweden.

* Address for correspondence; Tel: +237 67762 3220; Email: chongwa_ub@yahoo.co.uk

Abstract (Should be presented in one paragraph (do not separate sections) and should contain a maximum of 300 words)

Ex
A sensitive and specific test for the routine diagnosis of active Onchocerca infection is currently lacking. A major drawback in the development of such a test has been the paucity of knowledge of suitable parasite antigens that can serve as targets in antigen-detection assays. In the present study, we employed mass spectrometry as well as enzymes, bioinformatics and molecular biology techniques to identify and characterize several potentially diagnostic Onchocerca antigens in the in vivo nodular fluid, which is being investigated for the first time. The majority of the 25 identified antigens lacked a secretory signal. Two of them characterized in greater detail were a dominant secretory alkaline phosphates which appears to be rather unique, and a dominant circulating cytoplasmic intermediate filament protein, previously identified and named, OV1CF. The latter was also characterized with the aid of previously developed monoclonal antibodies (Mabs). We conclude that these in vivo-released products are promising targets for more sensitive and specific Mab-based antigen-detection tests for river blindness, especially when targeted in combinations.